ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

All Content

Results of a large trial have indicated that the use of interim PET/CT imaging has limited prognostic value to DLBCL patients being treated with R-CHOP-14.

A new meta-analysis suggests that de-escalation of bone-targeted agents is a safe strategy in breast cancer patients with bone metastases.

Advanced Hodgkin lymphoma patients who discontinue their treatment with bleomycin and vincristine as part of a BEACOPP regimen did not experience an effect on survival.

Ovarian cancer progression may be driven by the activation of an endoplasmic reticulum stress response factor that disrupts the function of dendritic cells and, subsequently, antitumor fighting T cells.

Two phase III trials have confirmed the benefit of regorafenib, an oral multikinase inhibitor, in patients with previously treated metastatic colorectal cancer.

A subgroup analysis of the phase III RECOURSE trial has shown that TAS-102 is effective at improving survival in patients with both KRAS wild-type or mutant metastatic colorectal cancer.

Treatment with FOLFOX plus cetuximab resulted in improved PFS vs FOLFOX alone in patients with metastatic colorectal cancer with “all-RAS” wild-type tumors.

Use of post-operative radiotherapy was associated with better overall survival in patients with incompletely resected stage II/III non-small-cell lung cancer.

Use of a VD regimen alone to treat patients with transplant-ineligible multiple myeloma was not inferior to VTD or VMP regimens, according to the UPFRONT trial.

Large proportions of lung and colorectal cancer patients believe that surgery will cure their cancer, according to results of a new population-based study.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.